Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Urigen Pharmaceuticals has announced that the US Patent and Trademark Office has issued the first patent for the use of URG101, an investigational, bladder instillation treatment for painful bladder syndrome or interstitial cystitis.
Subscribe to our email newsletter
This patent broadly covers the use of the URG101 product in the treatment of painful bladder syndrome or interstitial cystitis (PBS/IC). The term of the patent extends into 2025.
Urigen has also announced positive results from a Phase II study of URG101. The study was a multi-center, double-blind, placebo-controlled, crossover trial.
Findings from the study included, primary endpoint – improvement in average daytime pain (p=0.03), secondary endpoints – improvement in daytime urgency (p=0.03) and total symptom score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by Poris (p=0.01).
William Garner, president and CEO of Urigen, said: “We will continue to execute our intellectual property strategy to strengthen our proprietary position in the field of PBS/IC.”